Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials

BACKGROUND: Patients with episodic migraine (EM) with a higher-frequency of migraine headache days (HFEM: 8–14 migraine headache days/month) have a greater disease burden and a higher risk of progressing to chronic migraine (CM) with associated acute treatment overuse versus those with low-frequency...

Descripción completa

Detalles Bibliográficos
Autores principales: Jedynak, Jakub, Eross, Eric, Gendolla, Astrid, Rettiganti, Mallikarjuna, Stauffer, Virginia L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161994/
https://www.ncbi.nlm.nih.gov/pubmed/34049484
http://dx.doi.org/10.1186/s10194-021-01222-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161994/
https://www.ncbi.nlm.nih.gov/pubmed/34049484
http://dx.doi.org/10.1186/s10194-021-01222-w

Ejemplares similares